Chaoju Ophthalmology (02219) increased by 5%. As of press release, it was up 5% to HK$3.99, with a turnover of HK$11.14,900.
The Zhitong Finance App learned that Chaoju Ophthalmology (02219) increased by 5%. As of press release, it had risen 5% to HK$3.99, with a turnover of HK$11.14,900.
According to the news, Chaoju Ophthalmology announced its 2023 annual results, with revenue of $1,369.5 million (RMB, same below), up 38.3% year on year; profit attributable to parent company owners was $229 million, up 21.9% year on year; proposed final dividend of HK$0.2208 per share and special dividend of HK$0.0767 per share. As of December 31, 2023, the Group operated a network of 31 ophthalmology hospitals and 29 optometry centers, spanning a total of seven provinces and autonomous regions in China.
Guoyuan International previously pointed out that the company's business is deeply involved in Inner Mongolia, covering North China and East China. Inner Mongolia has obvious competitive advantages and extremely high barriers, which is the basic guarantee for the steady growth of the company's performance. Furthermore, in December 2023, the company completed the acquisition of 97% of the shares of Beijing Mingyue Ophthalmology Clinic Co., Ltd. (“Beijing Hospital”) at a cost of RMB 36.86 million. The establishment of Beijing Hospital is conducive to the collaborative cooperation of the company's high-quality medical volunteers in Beijing, Inner Mongolia and North China, improving the quality of medical services and cultivating new growth points.